Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma

被引:29
作者
Chen, F. [1 ]
Fujinaga, T. [1 ]
Sato, K. [1 ]
Sonobe, M. [1 ]
Shoji, T. [1 ]
Sakai, H. [1 ]
Miyahara, R. [1 ]
Bando, T. [1 ]
Okubo, K. [1 ]
Hirata, T. [1 ]
Date, H. [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Sakyo Ku, Kyoto 6068507, Japan
来源
EJSO | 2009年 / 35卷 / 06期
关键词
Lung; Metastasectomy; Soft tissue sarcoma; SURVIVAL; RESECTION; CHEMOTHERAPY;
D O I
10.1016/j.ejso.2008.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Resection for pulmonary metastasis from soft tissue sarcomas is an accepted method for treatment, but it is still debatable which patients will benefit from Surgical intervention. To find an entity of patients benefiting from pulmonary metastasectomy, we reviewed our institutional experience. Methods: Between 1990 and 2007, 23 patients with pulmonary metastases from soft tissue sarcomas underwent complete pulmonary resection. All patients had obtained locoregional control of their primary tumors. Various peroperative variables were investigated retrospectively to confirm the role of pulmonary metastasectomy and to identify possible prognostic factors for survival after metastasectomy. Results: Overall survival rate after metastasectomy was 43% and 29% at 5 and 10 years, respectively. Disease-free survival rate was 9% at 1 year after pulmonary resection. On multivariate analysis, no tumor recurrence (neither locoregional recurrence nor extrapulmonary metastasis) before pulmonary metastasis provided a significantly favorable overall survival (P = 0.038). In addition, repeat metastasectomy for recurrent pulmonary metastasis also provided a favorable overall survival (P = 0.041). Conclusions: Our data suggested that patients most likely to benefit from pulmonary metastasectomy for soft tissue sarcoma have no tumor recurrence before pulmonary metastasis. Furthermore, patients with repeat metastasectomy for recurrent pulmonary metastasis also presented a significantly longer survival. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:660 / 665
页数:6
相关论文
共 22 条
[1]  
Belal A, 2001, J CARDIOVASC SURG, V42, P835
[2]  
CASSON AG, 1992, CANCER, V69, P662, DOI 10.1002/1097-0142(19920201)69:3<662::AID-CNCR2820690311>3.0.CO
[3]  
2-I
[4]   Survival after pulmonary metastasectomy in soft tissue sarcoma - Prognostic factors in 214 patients [J].
Choong, PFM ;
Pritchard, DJ ;
Rock, MG ;
Sim, FH ;
Frassica, FJ .
ACTA ORTHOPAEDICA SCANDINAVICA, 1995, 66 (06) :561-568
[5]  
Downey Robert J, 2006, Thorac Surg Clin, V16, P133, DOI 10.1016/j.thorsurg.2006.03.001
[6]   RANDOMIZED STUDY OF SYSTEMIC CHEMOTHERAPY FOLLOWING COMPLETE EXCISION OF NONOSSEOUS SARCOMAS [J].
EDMONSON, JH ;
FLEMING, TR ;
IVINS, JC ;
BURGERT, EO ;
SOULE, EH ;
OCONNELL, MJ ;
SIM, FH ;
AHMANN, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) :1390-1396
[7]  
JABLONS D, 1989, J THORAC CARDIOV SUR, V97, P695
[8]   Cancer statistics, 2005 [J].
Jemal, A ;
Murray, T ;
Ward, E ;
Samuels, A ;
Tiwari, RC ;
Ghafoor, A ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (01) :10-30
[9]   RESPONSE TO CHEMOTHERAPY DOES NOT PREDICT SURVIVAL AFTER RESECTION OF SARCOMATOUS PULMONARY METASTASES [J].
LANZA, LA ;
PUTNAM, JB ;
BENJAMIN, RS ;
ROTH, JA .
ANNALS OF THORACIC SURGERY, 1991, 51 (02) :219-224
[10]  
Liebl LS, 2007, ANTICANCER RES, V27, P2897